CSL Limited

Headquarters: Parkville, VIC, Australia

Founded: 1916

Employees: 25,000

CEO: Mr. Paul R. Perreault B.A.

ASX: CSL -0.34%

Market Cap

A$139.10 Billion

AUD as of Jan. 1, 2024

US$94.74 Billion

Market Cap History

Company Description

CSL Limited is a biotechnology company providing products to treat and prevent serious human medical conditions. CSL is involved in the research, development, manufacturing, and marketing of a wide range of products including blood plasma derivatives, vaccines, antivenom, and cell culture reagents for medical and genetic research and manufacturing applications.

CSL Limited market capitalization over time

Evolution of CSL Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of CSL Limited

Detailed Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Top 1-year algo backtest: +191.38%

$10,000 in June 2023 would now be $29,138 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

CSL Limited has the following listings and related stock indices.

Stock: ASX: CSL wb_incandescent

Stock: FSX: CSJ wb_incandescent

Product & Services

blood plasma, vaccines, antivenom, other laboratory and medical products

Key People

Paul Perreault (CEO)


Revenue: AUD$10.61 billion (2021)

Net income: USD$1.919 billion (2019)



45 Poplar Road

Parkville, VIC 3052


Phone: 61 3 9389 1911

Fax: 61 3 9389 1434